<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article223</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/Ibrutinib-Rituximab_or_Chemoimmunotherapy_for_Chronic_Lymphocytic_Leukemia" style="display:block; margin-bottom:10px;">Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia Original</a></li>
<h2><strong>Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ibrutinib–Rituximab or Chemoimmunotherapy for CLL". The New England Journal of Medicine. 2019.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients 70 years of age or younger with previously untreated chronic lymphocytic leukemia (CLL), how does treatment with ibrutinib-rituximab compare with standard chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients 70 years of age or younger with previously untreated CLL, ibrutinib-rituximab therapy led to superior progression-free survival and overall survival compared with chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab has been the standard first-line treatment for younger, fit patients with CLL. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown efficacy in patients with relapsed/refractory and untreated CLL. This phase 3 trial demonstrated that ibrutinib in combination with rituximab was superior to standard chemoimmunotherapy in progression-free and overall survival in previously untreated patients younger than 70 years old with CLL.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines for CLL treatment reflect earlier data and may not yet include the combination of ibrutinib and rituximab as a frontline therapy in fit patients aged 70 or younger. These guidelines will likely be updated following the publication of this trial's results.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, open-label, randomized, phase 3 trial<br/>
- N=529<br/>
- Ibrutinib-rituximab (n=354)<br/>
- Chemoimmunotherapy with fludarabine-cyclophosphamide-rituximab (FCR) (n=175)<br/>
- Median follow-up: 33.6 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Previously untreated patients with CLL/SLL, ≤70 years old, appropriate for FCR treatment, no chromosome 17p13 deletion<br/>
- Exclusion Criteria: Details within Supplementary Appendix<br/>
- Baseline Characteristics: Median age 58 years, majority were male, Rai stage I-II in majority<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Ibrutinib-rituximab: Ibrutinib (420 mg/day) until disease progression + rituximab for 6 cycles<br/>
- Chemoimmunotherapy: Fludarabine + cyclophosphamide + rituximab for 6 cycles<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: Progression-free survival<br/>
  - 3-year survival: 89.4% ibrutinib-rituximab vs. 72.9% FCR, HR 0.35, 95% CI [0.22-0.56], P&lt;0.001<br/>
- Secondary Outcome: Overall survival<br/>
  - 3-year survival: 98.8% ibrutinib-rituximab vs 91.5% FCR, HR 0.17, 95% CI [0.05-0.54], P&lt;0.001<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- Indefinite therapy with ibrutinib has potential long-term side effects and cost implications.<br/>
- FCR has a proven long-term efficacy, particularly in patients with IGHV-mutated CLL.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- National Cancer Institute and Pharmacyclics (a subsidiary of AbbVie).<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- ClinicalTrials.gov number, NCT02048813<br/>
- Full NEJM article with supplementary material
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
